---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-053961"
form_type: "8-K"
ticker: "OFIX"
cik: "0000884624"
company_name: "Orthofix Medical Inc."
filed_at: "2024-05-07T23:59:59+00:00"
generated_at: "2026-06-02T21:27:54.480157+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Orthofix Q1: net sales $188.6M (+7.7%), net loss narrows to $36M; raises FY sales outlook to $790-795M

## Summary
- Net sales $188.6M, +7.7% YoY; Bone Growth Therapies +10%, U.S. Spine Fixation +16%, U.S. Orthopedics +23%.
- GAAP net loss $(36.0)M ($0.95 loss per share) vs $(60.9)M ($1.71) prior year; adjusted EBITDA $7.7M (4.1% of sales).
- FY2024 net sales guidance raised to $790-795M (from $785-795M); adjusted EBITDA guidance reaffirmed at $62-67M.
- Cash and cash equivalents $29.5M; $125M drawn on $150M credit facility.

## SEC filing metadata
- accession: 0000950170-24-053961
- form_type: 8-K
- ticker: OFIX
- cik: 0000884624
- company_name: Orthofix Medical Inc.
- filed_at: 2024-05-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/884624/000095017024053961/0000950170-24-053961-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/884624/000095017024053961/ofix-20240507.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-053961
- JSON: https://secwatch.observer/filing/0000950170-24-053961.json
- Plain text: https://secwatch.observer/filing/0000950170-24-053961.txt

## Key facts
- Earnings Releases
  Orthofix Medical Inc. reported the first quarter ended March 31, 2024 results: revenue $188.6 million, net income $(36.0) million, EPS $(0.95). Guidance raised.
  - Period: the first quarter ended March 31, 2024
  - Revenue: $188.6 million
  - Net income: $(36.0) million
  - EPS: $(0.95)
  - Guidance: raised
  - Result: reported results
  source text: assets, and any impairment of acquired goodwil --- EX-99.1 (EX-99.1) --- EX-99.1 Exhibit 99.1 Orthofix Reports First Quarter 2024 Results Recent Highlights • Net sales of $188.6 million, an increase of 7.7% on a reported basis and 7.5% on a constant currency basis over prior year • Bone Growth Therapies net sales growth of 10%, marking five consecutive quarters
  evidence_url: https://www.sec.gov/Archives/edgar/data/884624/000095017024053961/0000950170-24-053961-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.